4th Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$100,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Oppose medical device tariffs.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

Support repeal of medical device tax.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Copyright/Patent/Trademark CPT

Address concerns with provisions of patent litigation reform, including inter partes review. Support STRONGER Patents Act. Support Hatch Waxman Integrity Act. Oppose "march-in" rights and "compulsory licensing" proposals.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Health Issues HCR

Support FDA user fee programs and review process consistency and predictability. Support PAHPA re- authorization. Support policy improvements to address antimicrobial resistance.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Labor/HHS/Ed Appropriations: NIH, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation; FDA Appropriations; PTO Appropriations.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —

Contacted: Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

Support NIH research funding. Support implementation of 21st Century Cures Act.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —

Contacted: Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Address concerns with Medicare Advantage step therapy proposal. Support Advancing Access to Precision Medicine Act. Oppose changes to Medicare Advantage and Part D prescription drug benefit. Oppose International Pricing Index / reference pricing in Medicare Part B. Support Ensuring Patient Access to Critical Breakthrough Products Act.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.